DENARO, NERINA
 Distribuzione geografica
Continente #
NA - Nord America 511
EU - Europa 439
AS - Asia 72
OC - Oceania 1
Totale 1.023
Nazione #
US - Stati Uniti d'America 507
SE - Svezia 144
IE - Irlanda 143
CN - Cina 65
IT - Italia 40
FI - Finlandia 23
GB - Regno Unito 20
UA - Ucraina 17
DE - Germania 16
BE - Belgio 13
AT - Austria 10
FR - Francia 8
CA - Canada 4
IN - India 4
IR - Iran 3
NL - Olanda 2
RU - Federazione Russa 2
AU - Australia 1
LV - Lettonia 1
Totale 1.023
Città #
Dublin 142
Chandler 127
Nyköping 78
Jacksonville 52
Ann Arbor 25
Dearborn 24
Beijing 23
Cambridge 23
Princeton 23
Ashburn 21
Medford 19
Des Moines 16
Piemonte 13
Boardman 12
New York 12
Brussels 11
Lancaster 11
Vienna 10
Los Angeles 8
Woodbridge 7
Jinan 6
San Mateo 6
Shenyang 6
Leawood 5
Wilmington 5
Grammichele 4
Ardabil 3
Haikou 3
Messina 3
Nanjing 3
Tianjin 3
Toronto 3
Guangzhou 2
Hangzhou 2
Lanzhou 2
Nanchang 2
Ningbo 2
Taizhou 2
Tappahannock 2
Waanrode 2
Zhengzhou 2
Baotou 1
Changle 1
Changsha 1
Chongqing 1
Dalian 1
Hebei 1
Hendon 1
Kemerovo 1
Melbourne 1
Milan 1
Modena 1
Monmouth Junction 1
Montréal 1
Mountain View 1
Mumbai 1
Norwalk 1
Oxford 1
Pune 1
Ratoath 1
Seattle 1
Washington 1
Wenzhou 1
Totale 747
Nome #
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 80
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 70
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. 67
Gefitinib versus Erlotinib treatment in Non Small Cell Lung Cancer (NSCLC): comparison of two clinical experiences. 65
Impact of age on prognosis of locally advanced head and neck cancer (LAHNC) treated with chemoradiation (CRT). A single institution al experience 53
null 52
Cancer and stress: what’s matter? from epidemiology: the psychologist and oncologist point of view 48
Postoperative therapy in head and neck cancer: state of the art, risk subset, prognosis and unsolved questions. 46
MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer. 44
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 41
The effects on pain and activity of daily living caused by crusted exudation in patients with head and neck cancer treated with cetuximab and radiotherapy 40
Dysphagia in Head and Neck Cancer Patients: Pretreatment Evaluation, Predictive Factors, and Assessment during Radio-Chemotherapy, Recommendations. 40
IMPACT OF AGE ON PROGNOSIS OF LOCALLY ADVANCED HEAD AND NECK CANCER (LAHNC) TREATED WITH CHEMORADIATION(crt) A SINGLE INSTITUTIONAL EXPERIENCE. 39
The role of p53 and MDM2 in head and neck cancer 38
The Role of Antiangiogenic Agents in the Treatment of Head and Neck Cancer. 36
State-of-the-art and emerging treatment options in the management of head and neck cancer: news from 2013 34
Management of In-Field' Skin Toxicity in Head and Neck Cancer Patients Treated with Combined Cetuximab and Radiotherapy 33
A systematic review of current and emerging approaches in the field of larynx preservation 33
Strategies for Non-Resectable Head and Neck Cancer. 31
OP043 31
Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer. 30
The role of neck dissection after radical chemoradiation for locally advanced head and neck cancer: should we move back?. 30
Radiation-induced pemphigus vulgaris of the breast. 27
The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer. 22
Totale 1.030
Categoria #
all - tutte 4.007
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.007


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191 0 0 0 0 0 0 0 0 0 0 0 1
2019/2020113 7 3 2 1 1 21 19 11 14 8 24 2
2020/2021121 12 10 24 8 13 11 1 1 0 10 24 7
2021/2022152 2 22 0 8 2 0 7 6 2 23 35 45
2022/2023452 37 61 18 23 30 55 8 20 179 0 17 4
2023/202482 9 11 5 12 8 20 7 1 0 9 0 0
Totale 1.030